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Introduction
The androgen receptor (AR) is a member of the family of
steroid receptors. Functional ARs are required for development
of the male gender (Cunha et al., 1987). In addition, ARs play
a role in growth of prostate cancer (Feldman and Feldman,
2001; Trapman, 2001). Therefore, metastasized prostate
cancers are frequently treated with antiandrogens, such as
flutamide or bicalutamide (Casodex) (Small and Vogelzang,
1997). However, despite initial success, all patients eventually
show tumour relapse. There may be several causes of therapy
resistance, including changes in cell signalling pathways, AR
overexpression and mutation of the AR (Feldman and
Feldman, 2001; Trapman, 2001). The latter may lead to
activation of the AR by ligands other than the androgens
testosterone and 5-dihydrotestosterone (DHT), including
estrogens, glucocorticoids and adrenal androgens (Veldscholte
et al., 1992; Brinkmann and Trapman, 2000; Zhao et al., 2000;
Mizokami et al., 2004). Therapy also selects for AR mutants
that are activated by the applied antiandrogens (Veldscholte et
al., 1990; Hara et al., 2003). One of the AR mutations most
frequently found in antiandrogen-treated patients is a mutation
in codon 877, resulting in the replacement of threonine by
alanine AR(T877A) (Veldscholte et al., 1990; Taplin et al.,
2003). The mutation results in agonistic activity of OH-
flutamide (Veldscholte et al., 1990), the active metabolite of
flutamide (Katchen and Buxbaum, 1975). Recently, in a
bicalutamide-treated patient, a novel mutation was found,
resulting in substitution of tryptophan at position 741 by
cysteine AR(W741C) (Taplin et al., 2003). It was demonstrated
that this mutation enabled bicalutamide to act as an agonist
(Hara et al., 2003).
The intracellular distribution of ARs in the absence and
presence of ligand has been extensively studied in cell lines
using both immunocytochemistry (Jenster et al., 1991;
Simental et al., 1991) and green fluorescent protein (GFP)-
tagging (Georget et al., 1997; Poukka et al., 2000; Tyagi et al.,
2000; Avancès et al., 2001; Farla et al., 2004). In the absence
of ligand, ARs are predominantly localized in the cytoplasm
associated with a chaperone complex containing heat shock
proteins (Smith and Toft, 1993; Pratt and Toft, 1997; Stenoien
et al., 1999), keeping the AR in a high-affinity ligand-binding
conformation (Vanaja et al., 2002). Ligand binding induces
release from this complex and rapid translocation of AR to the
nucleus within 15-60 minutes of addition of androgen (Georget
et al., 1997; Poukka et al., 2000; Tyagi et al., 2000; Avancès
et al., 2001; Farla et al., 2004). In the nucleus ARs bind as
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The androgen receptor (AR) is essential for development of
the male gender and in the growth of the majority of
prostate cancers. Agonists as well as most antagonists
induce translocation of the receptor to the nucleus, whereas
only agonists can activate AR function. Antagonists are
therefore used in the therapy of metastasized prostate
cancer. To obtain insight into the mechanism by which
antagonists block AR function in living cells, we studied
nuclear mobility and localization of green fluorescent
protein (GFP)-tagged AR in the presence of either the
agonist R1881 or the antagonists bicalutamide and
hydroxyflutamide. As controls we investigated a non-DNA-
binding AR mutant (A573D) and two mutants (W741C and
T877A) with broadened ligand specificity. We demonstrate
that in the presence of R1881, AR localizes in numerous
intranuclear foci and, using complementary fluorescence
recovery after photobleaching (FRAP) approaches and
computer modelling, that a fraction of AR (~10-15%) is
transiently immobilized in a DNA-binding-dependent
manner (individual ARs being immobile for ~45 seconds).
By contrast, antagonist-bound GFP-AR showed no
detectable immobile fraction and the mobility was similar
to that of the R1881-liganded non-DNA-binding mutant
(A573D), indicating that antagonists do not induce the
relatively stable DNA-binding-dependent immobilization
observed with agonist-bound AR. Moreover, in the
presence of bicalutamide and hydroxyflutamide GFP-AR
was homogeneously distributed in the nucleus. Binding of
bicalutamide and hydroxyflutamide to GFP-AR(W741C)
and GFP-AR(T877A), respectively, resulted in similar
mobility and heterogeneous nuclear distribution as
observed for R1881-liganded GFP-AR. The live cell studies
indicate that the investigated antagonists interfere with
events early in the transactivation function of the AR.
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dimers to androgen-response elements (AREs) in promoters of
target genes (Roche et al., 1992; Claessens et al., 2001).
Addition of the antiandrogens OH-flutamide and bicalutamide
also resulted in translocation of ARs from the cytoplasm to the
nucleus (Jenster et al., 1993; Poukka et al., 2000; Tyagi et al.,
2000; Avancès et al., 2001; Tomura et al., 2001), although the
translocation in the presence of bicalutamide was slower and
incomplete (Poukka et al., 2000; Tyagi et al., 2000; Avancès et
al., 2001).
Ligand-activated steroid receptors, including estrogen
receptor  (ER) (Htun et al., 1999; Stenoien et al., 2000),
glucocorticoid receptor (GR) (van Steensel et al., 1995; Htun
et al., 1996) and mineralocorticoid receptor (MR) (Fejes-Tóth
et al., 1998) were distributed in the nucleus in a focal pattern.
Likewise agonist-liganded ARs were shown to accumulate in
foci in the nucleus (Tyagi et al., 2000; Avancès et al., 2001;
Tomura et al., 2001; Ochiai et al., 2003; Farla et al., 2004).
Interestingly, ARs only accumulated into foci with agonistic
and partial agonistic ligands, whereas antagonist-bound ARs
showed a more homogeneous nuclear distribution (Tyagi et al.,
2000; Avancès et al., 2001; Tomura et al., 2001). Recently, we
showed that ARs carrying a mutation in the DNA-binding
domain show a homogeneous intranuclear distribution,
indicating that the focal pattern depends on the DNA-binding
ability of the AR (Farla et al., 2004).
GFP technology and quantitative live cell imaging have
provided new insights in the mechanism of gene activation by
steroid receptors. We showed using fluorescence recovery
after photobleaching (FRAP) that agonist-bound ARs are
immobilized in a DNA-binding-dependent manner, the
average immobilization of a single AR being 1-2 minutes
(Farla et al., 2004). Others have shown that GFP-tagged GRs
exchange rapidly between the nucleoplasmic compartment
and a mouse mammary tumour virus (MMTV) promoter array
(McNally et al., 2000). The p160 coactivator glucocorticoid
receptor interacting protein 1 (GRIP1) displayed similar
dynamic interactions on this promoter repeat (Becker et al.,
2002). GFP-tagged GR (Schaaf and Cidlowski, 2003; Elbi et
al., 2004), ER and the p160 coactivator steroid receptor
coactivator 1 (SRC-1) (Stenoien et al., 2001b) showed reduced
intranuclear mobility in the presence of agonistic ligands
suggesting that they dynamically interact with immobile
elements in the nucleus, similar to the interaction of GRs with
the MMTV promoter array. The coactivators SRC-1 and
CREB binding protein (CBP) were shown to rapidly exchange
on a lac repressor ER chimera immobilized on an array of
lac operators (Stenoien et al., 2001a), again demonstrating
that interactions between steroid receptors and coactivators
are very dynamic. Likewise in chromatin immunoprecipitation
(ChIP) experiments, ER and AR as well as associated
coactivators have been shown to associate with transcription
initiation complexes in a cyclic manner, albeit with much
longer cycling times (in the order of minutes) (Kang et al.,
2002; Métivier et al., 2003; Reid et al., 2003) compared to the
residence times observed with FRAP (in the order of seconds).
In addition, ChIP results suggest that the AR in the presence
of bicalutamide binds to promoter regions of androgen
regulated genes, although it is unable to form an active
transcription complex (Kang et al., 2002; Masiello et al., 2002;
Shang et al., 2002; Kang et al., 2004), in contrast to DHT-
activated ARs.
To investigate the mechanism of action of antagonists, we
studied the intranuclear dynamics and localization of GFP-
tagged ARs in the presence of the non-steroidal antagonists
OH-flutamide and bicalutamide, and compared them with the
effects of the agonistic ligand R1881. We also studied mutant
ARs containing mutations in codons 741 or 877 of the AR
found in prostate cancer patients (Taplin et al., 1999; Taplin et
al., 2003). As mentioned above, certain AR antagonists can
activate transcription by these mutant ARs (Veldscholte et al.,
1990; Hara et al., 2003). Mobility, transcriptional activation
and the intranuclear focal distribution pattern of wild-type and
mutant androgen receptors in the presence of activating ligands
were highly correlated. We found the behaviour of wild-type
AR in the presence of bicalutamide or OH-flutamide to be
similar to that of the non-DNA-binding mutant AR(A573D),
suggesting that antiandrogens act by interfering with the stable
DNA binding of the AR.
Materials and Methods
Constructs
Generation of pGFP-AR and pGFP(A573D) constructs, coding for N-
terminally tagged GFP-AR fusion proteins of which the expression is
driven by a CMV promoter, has been described previously (Farla et
al., 2004). pGFP-AR(W741C) and pGFP-AR(T877A) were generated
by QuikChange site-directed mutagenesis (Stratagene, La Jolla, CA)
on pGFP-AR using sense primers, 5-CTGTCATTCAGTACTCCTG-
TATGGGGCTCATGGTGTTTG-3 and 5-CTGCATCAGTTCG-
CTTTTGACCTGCTA-3, and antisense primers 5-CAAACACCAT-
GAGCCCCATACAGGAGTACTGAATGACAG-3 and 5-TAG-
CAGGTCAAAAGCGAACTGATGCAG-3. Presence of mutations
was verified by sequencing.
Stock solutions of hormones
R1881 (Methyltrienolone) was purchased from NEN (Boston, MA);
OH-flutamide was obtained from Schering (Bloomfield, NJ).
Bicalutamide (Casodex) was a gift from AstraZeneca (Macclesfield,
UK). R1881 and OH-flutamide were diluted to 1 M and 1 mM stock
solutions respectively in ethanol. Stocks were stored at –20°C.
Bicalutamide stocks of 1 mM in ethanol were freshly prepared
directly before use.
Cell culturing and transactivation assays
Hep3B cells were cultured in MEM (Cambrex, East Rutherford, NJ)
supplemented with 2 mM L-glutamine, 100 U/ml Penicillin, 100
g/ml Streptomycin and 5% FBS (PAN Biotech GmbH, Aidenbach,
Germany). For confocal microscopy, cells were seeded on glass
coverslips in six-well plates. For transactivation assays Hep3B cells
were seeded at a density of 100,000 cells/well in 24-well plates. Cells
were transfected with 250 ng/well of AR expression construct and
500 ng/well of a luciferase reporter expression vector gene using
FuGENE 6 (Roche, Indianapolis, IN). Four hours prior to
transfection, the medium was changed to medium containing 5%
dextran charcoal-treated hormone-depleted FBS in the absence or
presence of 1 nM R1881, 1 M bicalutamide or 1 M OH-flutamide.
Twenty-four hours after transfection, cells were lysed in lysis buffer
(15% glycerol, 25 mM Tris-phosphate, pH 7.8, 1 mM DTT, 1%
Triton X-100 and 8 mM MgCl2). Luciferase activity was measured
by addition of an equal volume of lysis buffer containing luciferine
to cell lysates using Fluoroscan Ascent FL (Labsystems Oy, Helsinki,
Finland). Luciferase activities were normalized to the activity in the
presence of 1 nM R1881.
Journal of Cell Science 118 (18)
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Generation of stable cell lines
Stable cell lines expressing GFP-AR (mutants) were generated to
ensure GFP-AR protein was expressed at physiological levels. Hep3B
cells were transfected with 1 g/well plasmid DNA using FuGENE6
1 day after plating in six-well plates. After 24 hours, cells were
trypsinized and plated in medium supplemented with 800 g/ml
Geneticin (G418 sulfate, Sigma, St Louis, MO) in 10 cm tissue culture
dishes. Clones were selected and checked for appropriate GFP-AR
distribution and expression by confocal microscopy and western
blotting. Stable cell lines were maintained as normal Hep3B cells in
medium supplemented with 800 g/ml Geneticin.
Western blotting
Stable cell lines expressing GFP-tagged AR constructs were cultured
in 25 cm2 flasks and allowed to grow until fully confluent. Cells were
washed with DPBS and lysed in 250 l Laemmli buffer (50 mM Tris,
10 mM DTT, 10% glycerol, 2% SDS and 0.001% Bromophenol Blue).
Lysates were boiled and stored at –20°C. Lysates were subjected to
electrophoresis on a 10% SDS polyacrylamide gel using -actin
expression as loading control. Following electrophoresis, proteins
were transferred to nitrocellulose membranes. Blots were incubated
with monoclonal antibodies F39.4.1, directed against the AR N-
terminal domain (Zegers et al., 1991) or anti--actin (Sigma). Blots
were subsequently incubated with horseradish peroxidase (HRP)-
conjugated goat anti-mouse antibody (Dako, Glostrup, Denmark).
Proteins were visualized using Super Signal West Pico Luminol
solution (Pierce, Rockford, IL), followed by exposure to X-ray film.
Confocal microscopy
Cell imaging and FRAP studies were performed using a Zeiss
LSM510 Meta confocal microscope (Carl Zeiss, Jena, Germany)
using the 488 nm laser line of a 200 mW Ar laser with tube current
set at 6.1 A. All images and FRAP results were obtained using a
40/1.3 NA oil immersion lens using filters which pass emission light
between 505 and 530 nm. One day prior to confocal microscopy,
media were changed to MEM containing 5% dextran charcoal-
treated FBS. Prior to confocal microscopy, cell media were changed
to MEM containing 5% dextran charcoal-treated FBS with or
without 1 nM R1881, 1 M bicalutamide or 1 M OH-flutamide.
Cells were incubated with the ligands for at least 1 hour before they
were imaged or used for FRAP analysis.
FRAP nuclear mobility studies
Nuclear mobility in the presence of the various ligands was studied
using two different FRAP methods (Houtsmuller et al., 1999;
Houtsmuller and Vermeulen, 2001; Farla et al., 2004). In the first
method (strip-FRAP) fluorescence in a narrow strip (~0.75 m)
spanning the width of the nucleus was monitored every 21
milliseconds using 0.5% laser power of the 488 nm laser line, an
intensity at which no significant monitor bleaching was observed.
After 4 seconds the strip was bleached for 42 milliseconds at
maximum laser power. Fluorescence intensity in the strip was
expressed relatively to the fluorescence intensity before bleaching. All
graphs were normalized to relative fluorescence of GFP-AR(A573D)
in the presence of 1nM R1881 after complete redistribution (Farla et
al., 2004).
The second FRAP method uses a combination of FRAP and
fluorescence loss in photobleaching (FLIP), of which the principle has
been described previously (Hoogstraten et al., 2002; Farla et al.,
2004). Briefly, a strip of ~1.1 m was bleached at one pole of the
nucleus for 0.6 seconds at maximum laser power. Subsequent post-
bleach images were taken at 3-second intervals. Fluorescence
intensities in the bleached strip and in a strip 10 m from the bleached
area were normalized to prebleach intensities. Differences in
fluorescence ratio between the bleached strip (FRAP) and distal
region of the nucleus (FLIP) were calculated at each time point after
bleaching. Maximal difference was set to 1 and values of the
individual cells in the experiments were averaged. For both FRAP
methods nuclei were selected with similar expression levels and
similar dimensions.
For analysis of FRAP assays, experimental data were fitted to
curves generated by computer software we developed to simulate
FRAP of fluorescent molecules inside a finite ellipsoid volume
representing the nucleus. Simulations were performed using fixed,
experimentally obtained parameters, describing lens properties (beam
shape and 3D intensity distribution, during monitoring and during
bleach pulse), GFP properties (quantum yield, susceptibility to
bleaching) and nuclear properties (size and shape). Details on the
simulations have been reported (Farla et al., 2004). Three protein
mobility parameters, diffusion coefficient, bound fraction and
duration of binding of individual molecules were varied. The three-
dimensional diffusion constant (Deff) was defined as [(stepsize2)/6 
cycletime]. The values of the parameters reported here are smaller
than reported previously. This is because we used an improved
microscope system, which enabled us to measure very soon after the
bleach pulse. Furthermore the improved sensitivity of the detector
allowed monitoring of the cells at low laser intensities, where no
monitor bleaching occurs, whereas previously correction for monitor
bleaching may have resulted in an overestimation of the binding times.
The Deff values reported here differ from those reported previously
(Farla et al., 2004), because a one-dimensional model was used to fit
the data. All simulations were performed five times and averaged; the
average s.d. at each point of the simulation curves was <0.01. Least-
square fitting of averaged simulated curves was used to determine
which curves fitted best to the experimental data. Mobility parameters
for all curves with (xt – yt)2/n less than 0.002 were averaged, where
xt and yt represent the value of the experimental data and the
simulation at a given time point of the curve, respectively, and n is
the number of time points. Mann-Whitney U-tests were performed to
assess statistical significance of differences in mobility parameters of
GFP-AR (mutants) compared with GFP-AR(A573D).
Results
In previous work we studied the transcriptional activity,
intranuclear distribution and mobility of the GFP-tagged wild-
type AR using live cell microscopy and FRAP (Farla et al.,
2004; Houtsmuller, 2005). To determine the role of DNA
binding, we compared the wild-type AR with an AR containing
a mutation in the DNA-binding domain (A573D) that disrupts
promoter binding, but is unaffected with respect to ligand
binding (Brüggenwirth et al., 1998) and transport from
cytoplasm to the nucleus (Farla et al., 2004). To investigate the
mechanism of action of AR antagonists, we investigated the
effect of bicalutamide and OH-flutamide on the intranuclear
mobility and localization of GFP-AR and GFP-AR(A573D)
(Fig. 1A). In addition, we studied two AR mutants, implicated
in resistance to prostate cancer treatment with these non-
steroidal AR antagonists (Veldscholte et al., 1990; Taplin et al.,
1999; Hara et al., 2003; Taplin et al., 2003). The first mutant
has a base substitution in codon 741 of the AR coding
sequence, resulting in substitution of Trp741 by Cys (Hara et
al., 2003). The second mutant has a base substitution of Thr877
by Ala (Veldscholte et al., 1990). The cDNA expression
constructs coding for GFP-tagged versions of these AR
mutants were transfected in the AR-negative cell line Hep3B
and allowed to stably integrate. Western blot analyses revealed
that all stable cell lines expressed full-length GFP-AR (Fig.
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1B). Expression in the GFP-AR stable cell line is comparable
to the levels of AR in the prostate cancer cell lines LNCaP and
PC346 (Fig. 1B) (Farla et al., 2004), indicating that GFP-AR
is expressed at physiological levels. As expression levels of the
mutants GFP-AR(W741C) and GFP-AR(T877A) were similar
or slightly less than that of wild-type GFP-AR, the effects we
observed were unlikely to be caused by overexpression.
To test the transactivating capacity of the GFP-tagged AR
mutants, their corresponding cDNA expression plasmids were
co-transfected with androgen-regulated promoters in AR-
negative Hep3B cells. Activation of either the minimal
promoter (ARE)2TATA (Fig. 1C) or the mouse mammary
tumour virus (MMTV)-promoter (Fig. 1D) in the presence of
R1881, or the antiandrogens OH-flutamide or bicalutamide
was measured. As expected, the non-DNA-binding mutant
GFP-AR(A573D) was inactive. Wild-type AR could activate
transcription of the (ARE)2TATA promoter in the presence of
R1881, whereas OH-flutamide and bicalutamide did not
activate transcription, as expected. The prostate cancer-related
GFP-tagged W741C mutant (Taplin et al., 2003) was activated
by bicalutamide to the same extent as by R1881, whereas GFP-
AR(T877A) in addition to R1881 was also activated by OH-
flutamide (Fig. 1C). The same ligand specificity was observed
on the MMTV promoter, although there were some
quantitative differences in transactivating capacity between the
mutants (Fig. 1D). These results show that the GFP tag does
not interfere with the transactivating properties of the studied
AR mutants, as the response is similar to results reported
previously with untagged ARs (Veldscholte et al., 1990; Hara
et al., 2003).
Antiandrogens OH-flutamide and bicalutamide do not
reduce the mobility of wild-type androgen receptors
Previously we have shown using FRAP that binding of R1881
to GFP-AR resulted in a strongly reduced mobility of nuclear
GFP-AR (Farla et al., 2004), when compared to a mutant GFP-
AR(A573D), which is unable to bind DNA (Brüggenwirth et
al., 1998). In this investigation we repeated these experiments
as controls. Using two complementary FRAP assays (Fig. 2A-
D) we show that fitting the data of the two assays to a model
of free diffusion yields different diffusion coefficients,
Journal of Cell Science 118 (18)
Fig. 1. Schematic representation, expression and transactivating capacity on androgen-regulated promoters of GFP-AR proteins investigated.
(A) As well as GFP-tagged wild-type AR, ARs containing a mutation in the DBD disrupting DNA-binding (Brüggenwirth et al., 1998), or in
helix 3 (W741C) or helix 12 (T877A) of the AR LBD, which result in altered ligand specificity (Veldscholte et al., 1990; Hara et al., 2003)
were studied. TAD, Transactivating domain; DBD, DNA-binding domain; LBD, Ligand binding domain. (B) Hep3B cells containing stably
integrated GFP-AR expression constructs and AR expressing prostate cancer cell lines were cultured for 1 day in the absence (lanes 1-6) or
presence of 1 nM R1881 (lanes 7-12). Cell lysates were prepared and subjected to western blotting. Western blots of cell lysates from Hep3B
cells (AR negative) containing GFP-AR (lanes 1 and 7), GFP-AR(A573D) (lanes 2 and 8), GFP-AR(W741C) (lanes 3 and 9) or GFP-
AR(T877A) (lanes 4 and 10) and LNCaP (lanes 5 and 11) and PC346 (lanes 6 and 12) using an anti-AR or -actin antibody. -actin expression
was used as a loading control. (C,D) Co-transfection assays of GFP-AR and the mutants depicted in A with androgen-regulated promoter
constructs (ARE)2-TATA-luciferase (C) and mouse mammary tumour virus (MMTV) luciferase (D) in the presence of 10–9 M R1881, 10–6 M
bicalutamide (Bic), 10–6 M OH-flutamide (OH-F) or no ligand as indicated. Luciferase activity of the GFP-AR proteins is plotted relative to
activity of GFP-AR in presence of 10–9 M R1881. Mean±s.e.m. of at least three independent experiments are shown.
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Fig. 2. Combined strip-FRAP and FLIP-FRAP reveal that a fraction of agonist-liganded GFP-ARs is transiently immobilized. (A) The strip-
FRAP method. A strip in the centre of a nucleus is bleached (red rectangle) with high laser power. Subsequently, fluorescence in the strip is
measured at regular time intervals. Images are shown in false colour to visualize fluorescence differences more clearly. (B) Combined FLIP and
FRAP method (FLIP-FRAP). A strip at one pole of the nucleus was bleached for a relatively long period. The difference between fluorescence
signals in the bleached region (FRAP, red rectangle) and a distal region at 10 m from the bleached region of the nucleus (FLIP, yellow
rectangle) was determined at regular time intervals. (C,D) Strip-FRAP and FLIP-FRAP experiments of GFP-AR or the non-DNA-binding
mutant GFP-AR(A573D) in the presence of 10–9 M R1881. (C) Graph showing fluorescence intensities relative to complete redistribution of the
non-DNA-binding mutant GFP-AR(A573D) in the presence of R1881 plotted as a function of time. Mean values of at least ten cells of a
representative experiment are plotted. All experiments were performed at least three times. (D) Graph showing the difference between
fluorescence intensity in the FLIP and FRAP regions (rectangles in B) relative to the difference directly after bleaching, plotted against time.
Mean values±two times the s.e.m. of two independent experiments on at least ten cells are plotted. (E,F) Computer simulations (see Materials
and Methods) of strip-FRAP and FLIP-FRAP of freely diffusing molecules do not explain the experimental FRAP data obtained with both
methods. D is the effective diffusion coefficient. Experimental strip-FRAP data on wild-type GFP-AR lies in between curves representing
indicated scenarios of free diffusion (E), whereas experimental FLIP-FRAP data on wild-type GFP-AR lies outside these boundaries (F). (G,H)
Computer simulations representing a model where, next to freely diffusing molecules, a fraction is transiently immobilized, fitted to both strip-
FRAP and FLIP-FRAP experimental curves on wild-type GFP-AR. Computer simulations correspond to the average of best fits of FRAP and
FLIP-FRAP experiments respectively (Table 1), so are not necessarily the best fits of the individual experiments. Absolute value of residuals of
the computer simulation fit and the experimental data on each time point are plotted below the x-axis.
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indicating that the results cannot be explained by a simple
model of free diffusion. Therefore, the observed slower
mobility is probably not the result of an overall slow-down of
diffusion (Fig. 2E,F). By contrast, a scenario where a ~15%
fraction of ARs in the nucleus was immobilized for ~45
seconds (Fig. 2G,H and Table 1) fitted well to both strip-FRAP
and FLIP-FRAP curves. The R1881-liganded DBD mutant
GFP-AR(A573D) was freely mobile, similar to unliganded
wild-type ARs (Farla et al., 2004), suggesting that the
immobilization of wild-type AR was related to binding to its
cognate sequences in the DNA. To investigate the mechanism
by which AR antagonists OH-flutamide and bicalutamide
interfere with proper transcription activation we set out to
compare the behaviour of R1881-associated wild-type AR with
that of antagonist-liganded wild-type ARs. First, we performed
strip-FRAP and FLIP-FRAP assays on cells expressing wild-
type ARs in the presence of OH-flutamide (Fig. 3A,B). Fitting
of the experimental data to computer-simulated curves revealed
no significant slow-down of AR mobility, compared to the non-
DNA-binding GFP-AR(A573D) (Fig. 3A,B; Table 1).
Diffusion constants in both strip-FRAP and FLIP-FRAP
experiments were similar to that of GFP-AR(A573D). Similar
to these results, the combined FRAP analysis of wild-type AR
in the presence of the antagonist bicalutamide showed almost
identical recovery kinetics as GFP-AR(A573D) indicating that
no substantial immobilization occurred (Fig. 3C,D; Table 1).
These results suggest that antagonist-liganded ARs have a
similar mobility to the non-DNA-binding GFP-AR(A573D)
and show no immobilization, whereas the agonistic ligand
R1881 induces a transient immobilization of a fraction of ARs
in a DNA-binding-dependent manner. These data suggest that
antagonist-bound ARs cannot stably bind DNA.
Androgen receptor agonists induce intranuclear foci
In the absence of ligand, GFP-AR as well as GFP-AR(A573D)
are predominantly localized in the cytoplasm, although not
completely absent from the nucleus (Farla et al., 2004). As
shown previously, R1881 induced translocation to the nucleus
and in addition to AR immobilization, induced intranuclear AR
accumulation in a focal pattern (Fig. 4A) (Farla et al., 2004).
By contrast, the DBD mutant GFP-AR(A573D) was
homogeneously distributed in the nucleus (Fig. 4D) (Farla et
al., 2004). We studied the intranuclear distribution of GFP-AR
and GFP-AR(A573D) in the presence of OH-flutamide or
bicalutamide by high-resolution confocal microscopy.
Addition of the antagonists translocated the receptor to the
nucleus (although at a slower rate) and resulted in a
homogeneous intranuclear distribution of wild-type AR (Fig.
4B,C) (see also Tyagi et al., 2000; Avancès et al., 2001; Tomura
et al., 2001; Farla et al., 2004) as well as the DBD mutant GFP-
AR(A573D) (Fig. 4E,F), indicating that the binding of
antagonists prevented foci formation.
Next, we studied the intracellular distribution of GFP-
AR(W741C) and GFP-AR(T877A). In the absence of ligand,
those mutants similar to wild-type receptors were
predominantly cytoplasmic. Exposure to R1881 as well as the
antagonists OH-flutamide and bicalutamide resulted in
translocation of the mutant receptors to the nucleus (Fig. 4G-
L). In the presence of R1881, GFP-AR(W741C) and GFP-
AR(T877A) displayed a very similar focal distribution (Fig.
4G,J). GFP-AR(W741C), which activates transcription on
androgen-regulated promoters in the presence of bicalutamide
(Hara et al., 2003) (Fig. 1C,D), in addition showed
bicalutamide-induced intranuclear accumulations (Fig. 4I),
whereas OH-flutamide treatment resulted in a homogeneous
intranuclear distribution (Fig. 4H), supporting the hypothesis
that lack of transactivating capacity results in homogeneous
distribution. Treatment of the mutant GFP-AR(T877A) with
OH-flutamide induced intranuclear accumulation (Fig. 4K),
but bicalutamide did not result in accumulation of this AR
mutant (Fig. 4L), consistent with transactivation of androgen-
regulated target genes by OH-flutamide and not by
bicalutamide (Fig. 1) (Veldscholte et al., 1990).
Journal of Cell Science 118 (18)
Table 1. Fit of experimental data to curves generated by computer simulation
  Ligand
Construct Parameter       R1881 OH-F Bic
    
GFP-AR Diffusion constant† 2.3±0.3** 3.4±0.2* 3.7±0.2
 Immobile fraction‡ 0.13±0.01** – –
 Binding time§ 45±5 – –
GFP-AR(A573D) Diffusion constant 3.0±0.2 3.7±0.2 3.5±0.2
 Immobile fraction – – –
 Binding time – – –
GFP-AR(W741C) Diffusion constant 2.2±0.3** 3.6±0.3 2.8±0.3**
 Immobile fraction 0.13±0.01** – 0.10±0.02**
 Binding time 52±7 – 33±5
GFP-AR(T877A) Diffusion constant 2.4±0.3** 2.6±0.2** 3.5±0.2
 Immobile fraction 0.14±0.01** 0.11±0.01** –
 Binding time 45±6 39±5 –
Data are the mean±two times s.e.m. of best fitting parameters from Strip-FRAP and FLIP-FRAP. Values in shaded areas indicate conditions with 
transcriptionally active ARs (see Fig. 1). 
†Diffusion constant in μm2/second of mobile fraction.
‡Fraction of receptors immobilized owing to interaction with subnuclear structures. –, no detectable immobile fraction (fraction <0.05). 
§Mean immobilization of individual ARs in seconds. 
P-values of Mann-Whitney U test comparing the value of the parameter with that of GFP-AR(A573D) with the same ligand, *P<0.05 and **P<0.005.
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Fig. 3. In the presence of antagonists OH-flutamide and bicalutamide GFP-AR shows no or little DNA-dependent immobilization. Strip-FRAP
(A,C) or combined FLIP and FRAP (B,D) of GFP-AR or the non-DNA-binding mutant GFP-AR(A573D) in the presence of 10–6 M OH-
flutamide (A,B) or 10–6 M bicalutamide (C,D). Experimental settings were identical to those described in Fig. 2. Lower graphs show computer
simulations corresponding to the average of best fits of strip-FRAP and FLIP-FRAP models of wild-type GFP-AR (see Table 1). The absolute
values of the residuals of the fit and the experimental data are plotted below the x-axis. Larger residuals in the first second of strip-FRAPs are
probably due to larger variation in the beginning of the experiment, when fluorescence changes rapidly.
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Prostate cancer-related androgen receptor mutants
show reduced mobility in the presence of their agonistic
ligands
The intranuclear mobility of the mutant receptors GFP-
AR(W741C) and GFP-AR(T877A) in the presence of R1881
was similar to wild-type AR (compare Fig. 5A,B with Fig.
2C,D). Fitting to computer-simulated curves revealed that ~10-
15% of ARs were immobilized for ~45 seconds (Table 1). In
addition, diffusion of the mobile fraction was slowed down
significantly compared to GFP-AR(A573D). The antiandrogen
OH-flutamide retarded redistribution of GFP-AR(T877A) (Fig.
5C,D), in agreement with OH-flutamide acting as an agonist of
this mutant (Fig. 1C,D). Computer simulations showed a
fraction (13%) of OH-flutamide-liganded GFP-AR(T877A)
was immobilized in a similar manner to R1881-bound wild-
type AR (Table 1). In addition, diffusion of the mobile fraction
was significantly slower compared to the other GFP-ARs in the
presence of OH-flutamide (Table 1). Similarly, bicalutamide
slowed down nuclear redistribution of GFP-AR(W741C) (Fig.
5E,F). By contrast, GFP-AR(T877A) showed the same FRAP
kinetics as GFP-AR(A573D), suggesting that no substantial
stable DNA binding occurs in the presence of bicalutamide. In
conclusion, the slower recovery of fluorescence in the presence
of agonistic ligands is probably caused by DNA-binding-
dependent immobilization of ~10-15% of ARs for ~45
seconds, usually accompanied by a slow-down in diffusion of
the mobile fraction (Table 1, Fig. 5).
Discussion
To obtain insight in the mechanism of the blocking of AR
transcription activation by antagonists, we investigated the
behaviour of the AR in living cells in the presence of
bicalutamide and OH-flutamide. Using FRAP on GFP-tagged
ARs to determine intranuclear mobility, we show that a fraction
(~10-15%) of agonist R1881-liganded ARs are immobilized
for ~45 seconds (Fig. 2C-H, Table 1). Immobilization is
dependent on DNA binding, as the mutant GFP-AR(A573D)
containing a mutation that completely disrupts DNA binding
(Brüggenwirth et al., 1998) did not show an immobile fraction
(Fig. 2C,D) (Farla et al., 2004). Similar high mobility was
observed for other AR-DBD mutants (V581F and R585K),
which do not bind DNA (data not shown). Binding of the AR
antagonists bicalutamide and OH-flutamide resulted in a
similar relatively high mobility as observed for the non-DNA-
binding mutant AR (Fig. 3), strongly suggesting that the
antagonists interfere with early steps in the mechanism of AR
transcription activation: stabilizing binding to promoters and
enhancers of androgen regulated genes. This is supported by
previous observations in vitro showing that bicalutamide-
liganded AR, but not R1881-liganded AR, could be removed
from the nuclear fraction by detergent treatment (Berrevoets et
al., 1993). However, studies using ChIP suggested that
bicalutamide-bound ARs (Kang et al., 2002; Masiello et al.,
2002) were present in DNA-protein complexes containing the
corepressors N-CoR and SMRT on the promoter/enhancer
region of androgen-regulated prostate-specific antigen (PSA)
(Cleutjens et al., 1997; Shang et al., 2002; Kang et al., 2004).
Assuming that the formation of DNA-bound repressor
complexes is not a unique feature of the PSA gene, it is
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Fig. 4. Activation of AR by agonistic ligands results in intranuclear
localization in foci. Confocal laser-scanning microscope images
showing representative nuclei of Hep3B cell lines stably expressing
GFP-AR (A-C), the non-DNA-binding mutant GFP-AR(A573D) (D-
F) or GFP-AR proteins with mutations in the LBD (which result in
altered ligand specificity), GFP-AR(W741C) (G-I) and GFP-
AR(T877A) (J-L). Subnuclear localization was observed in the
presence of 10–9 M R1881 (A,D,G,J), 10–6 M OH-flutamide
(B,E,H,K) or 10–6 M bicalutamide (C,F,I,L). With all ligands,
androgen receptors are localized in the nucleus, but are excluded
from nucleoli (dark areas in the nucleus). In situations where AR is
able to activate transcription intranuclear foci are observed
(A,G,I,J,K, see Fig. 1). Bar, 5 m.
Fig. 5. Prostate cancer-related AR-LBD mutants display reduced
mobility in the presence of their agonistic ligands. Nuclear mobility
of antiandrogen-resistant prostate cancer mutants AR(T877A) and
AR(W741C) was investigated using two complementary FRAP
assays (see also Fig. 2): strip-FRAP (A,C,E) and combined FLIP and
FRAP (B,D,F). Intranuclear mobility of these mutants in the
presence of 10–9 M R1881 (A,B), 10–6 M OH-flutamide (C,D) or
10–6 M bicalutamide (E,F) was studied. Mobility of non-DNA-
binding GFP-AR(A573D) is plotted as a reference. Experimental
settings were identical to those described in Fig. 2. Lower graphs in
C-F show computer simulations corresponding to the average of best
fits of strip-FRAP and FLIP-FRAP models (data in Table 1) of the
experimental curves of GFP-AR(T877A) (C,D) and GFP-
AR(W741C) in the presence of 1 M OH-flutamide (C,D) or
bicalutamide (E,F). Absolute values of the residuals of computer-
simulated curves and experimental data are plotted below the x-axis.
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expected that antagonist-bound ARs also bind to other AR-
specific promoters or enhancers. Although this seems to
contradict the data presented here (Fig. 3C,D and Table 1), it
may be that repressor complexes on promoters are very short-
lived (<1 second) and escape detection by FRAP.
In addition to the observed transient immobilization, R1881
also induced a slow-down of the effective diffusion of the
mobile AR fraction, which was not observed after antagonist
binding (Table 1). There are two explanations for this
observation. First, mobile agonist-bound ARs in the
nucleoplasm may, in contrast to antagonist-bound ARs,
associate with coactivators forming large complexes exhibiting
slower diffusion owing to their size. This view is supported by
published data indicating that binding of antagonists results in
a conformation of the AR-LBD that does not allow AR
amino/carboxyl-terminal (N/C) interaction (Doesburg et al.,
1997; Chang and McDonnell, 2002) and interactions with
coactivators (Chang and McDonnell, 2002; Shang et al., 2002).
A second explanation may be that the R1881-induced ability
to bind DNA not only leads to relatively stable binding to AR-
regulated promoters, but also to very transient, highly frequent
binding to non-specific regions in the DNA. Such a scenario in
which DNA interacting proteins ‘scan’ DNA in order to find
their cognate binding sites has been suggested previously
(Karpova et al., 2004; Phair et al., 2004; Sprague et al., 2004).
For instance, it was reported that the glucocorticoid receptor
binds very transiently (<200 milliseconds) to DNA with a very
high frequency, such that on average 80% of the GR is
associated with DNA (Sprague et al., 2004). Although such a
model does not completely explain our results of combined
strip-FRAP and FLIP-FRAP experiments (as our data fit better
to a model in which a small fraction is more stably
immobilized), it is possible that the observed large mobile AR
fraction (85-90%) exhibits this type of rapid interaction,
resulting in the measured slow-down of this mobile fraction.
We further studied the effect of OH-flutamide and
bicalutamide on the nuclear behaviour of two mutant ARs
(T877A and W741C) (Figs 4, 5), which were found in prostate
cancer patients treated with OH-flutamide and bicalutamide,
respectively (Taplin et al., 2003). OH-flutamide can activate the
transcription function of the T877A mutant and similarly,
bicalutamide can activate the W741C mutant (Veldscholte et al.,
1990; Hara et al., 2003) (Fig. 1C,D). It has been suggested that
binding of OH-flutamide to AR containing the T877A mutation
induces a conformation of the AR-LBD that allows AR N/C
interaction and coactivator interaction (Doesburg et al., 1997;
Chang and McDonnell, 2002; Shang et al., 2002), which results
in agonistic activity of OH-flutamide. A similar mechanism
may explain the agonist effect of bicalutamide on AR(W741C).
Our data are in agreement with this hypothesis as both mutants,
when exposed to bicalutamide (W741C) or OH-flutamide
(T877A), showed the same kinetics as the R1881-liganded AR,
i.e. all three mobility parameters measured here were in the
same range (~10-15% transiently immobile for 30-40 seconds,
as well as a slow-down of the mobile fraction (Fig. 5 and Table
1). As discussed above, this slow-down of diffusion can either
be explained by very transient binding events or engagement of
AR in larger complexes, or both.
The focal nuclear distribution pattern observed for agonist-
bound wild-type AR is a common feature of steroid receptors.
It has been described not only for AR (Tyagi et al., 2000;
Tomura et al., 2001), but also for the ER (Stenoien et al.,
2000) and GR (Htun et al., 1999). Here we show that there is
a direct relationship between transactivating capacity, reduced
mobility (as a consequence of transient binding) and the
occurrence of the focal pattern: in the presence of an agonistic
ligand all three features are observed together, irrespective of
whether the agonist is an antiandrogen activating a mutant or
R1881 activating wild-type AR or AR(W741C) and
AR(T877A) mutants. By contrast, in the presence of an
antagonist, all three features were absent, i.e. the nuclear
distribution was diffuse, mobility was not reduced, and no
transactivating capacity was observed. Previously, it was
suggested that the focal pattern reflects binding to the nuclear
matrix (Stenoien et al., 2000; Schaaf and Cidlowski, 2003;
Stavreva et al., 2004). However, this is contradicted by
observations that bicalutamide-bound ARs were also found in
the operationally defined nuclear matrix fraction (Tyagi et al.,
2000), although they did not appear in foci (Fig. 4) (Tyagi et
al., 2000; Tomura et al., 2001). For the aryl hydrocarbon
receptor it was shown that foci correlated with transcription
sites (Elbi et al., 2002) whereas for the GR, no clear correlation
of foci with pre-mRNA synthesis sites could be demonstrated
(van Steensel et al., 1995). Our results (Fig. 4) and that of our
previous studies (Farla et al., 2004) strongly suggest a role for
DNA binding in foci formation.
In conclusion, we have shown that, in contrast to R1881
binding, binding of the antagonists bicalutamide and OH-
flutamide to AR did not induce detectable DNA-binding-
related immobilization; did not give rise to a slow-down of the
effective diffusion of the mobile fraction; and did not induce
the formation of heterogeneous intranuclear distribution (foci).
These three observations strongly suggest that the investigated
antagonists interfere with events early in the transactivation
function of AR leading to the absence of stable DNA-binding-
dependent immobilization. This may be due to the absence of
appropriate stabilizing interactions with cofactors. In cell lines
expressing AR mutants GFP-AR(W741C) and GFP-
AR(T877A) bicalutamide and OH-flutamide induce
intranuclear immobilization and localization in numerous
irregular shaped foci respectively, suggesting that these
mutations restore the appropriate AR configuration and the
capacity to stably bind to DNA.
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